Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 54 of the 54 references it cites were found in a registry or an index.
Abstract
CFU of HN019/day for constipation. A total of 228 adults who were diagnosed with functional constipation according to the Rome III criteria were randomized in a double-blind and placebo-controlled trial. Colonic transit time (CTT), the primary outcome, and secondary outcomes that were measured using inventories-patient assessment of constipation symptoms (PAC-SYM) and quality of life (PAC-QoL), bowel function index (BFI), bowel movement frequency (BMF), stool consistency, degree of straining, bowel emptying, bloating, and pain severity-were assessed. Ancillary parameters and harms were also evaluated. There were no statistically significant differences in the primary or secondary outcomes between interventions. A post hoc analysis of 65 participants with fewer than 3 bowel movements per week (BMF ≤ 3/week) showed a physiologically relevant increase in weekly BMF in the high- (+2.0) and low-dose (+1.7) HN019 groups-by RMANOVA, the HN019 groups with BMF ≤ 3/week, pooled together, had a higher BMF versus placebo (P value = 0.01). Thus, improving low stool frequency could be a target of future interventions with HN019. High-dose HN019 also decreased the degree of straining at Day 28 versus placebo in those with BMF ≤ 3/week (P value = 0.02). Three unlikely related AEs-2 with low-dose HN019 and 1 with placebo-were followed until full recovery. In conclusion, although there were no differences in the primary analysis, HN019 is well tolerated and improves BMF in adults with low stool frequency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bifidobacterium animalis subsp lactis HN019 (HN019) has been shown to improve constipation and gastrointestinal tract symptoms in adults at doses ranging from 1.0 × 109 to 17.2 × 109 colony-forming units (CFU)/d for 2 to 4 weeks.5,6”
From Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This increase in the placebo group is in line with what was observed earlier for the placebo group in the ITT population of Ibarra and coworkers5 and is likely a placebo effect.”
From Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HN019, the strain investigated in the present study, has been reported to improve BMF in people with constipation.5,6”
From Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Rome III criteria for functional constipation require a minimum of 2 of 5 criteria to be met for diagnosis, introducing the potential for substantial heterogeneity in a study population.5”
From Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the primary outcome (CSBMs per week) contrast with earlier reports.5,6”
From Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial (2024) · cites this paper as [5]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72352 · Cited by 2,165
Hagströmer, M., Oja, P., & Sjöström, M. (2006) · Public Health Nutrition · doi:10.1079/phn2005898 · Cited by 1,958 · cited 1×
“On Days 0 and 28, the short version of the International Physical Activity Questionnaire (IPAQ) was answered.(22) Before the visits on Days 0 and 28, they supplied their 24-h food recall—total calories (Kcal), total carbohydrates (g and %Kcal), total lipids (g and %Kcal), total proteins (g and %Kcal), alcohol (g and %…”
MethodBetter Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · cited 1×
“The study has been reported per the CONSORT statement.(19,20)”
MethodThe Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,390
Suares, N. C., & Ford, A. C. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.164 · Cited by 904 · cited 1×
“Chronic idiopathic constipation, a gastrointestinal (GI) disorder of colonic or anorectal function, affects 14% of the population worldwide.(1) Historically, health care professionals have defined constipation as fewer than 3 bowel movements per week.”
BackgroundFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Research works printed but not linked: 4
- WHO, Guidelines for ATC Classification, 1993, 23
- Miller LE, 2017, Annals of Gastroenterology, 30, 161
- Fateh R, 2010, Swiss medical weekly, 141, w13239
- Bian Z, 2013, Hong Kong medical journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine, 19, 44
Cited by
Clostridium species as probiotics: potentials and challenges
Guo, P., Zhang, K., Ma, X., & He, P. (2020) · Journal of Animal Science and Biotechnology · doi:10.1186/s40104-019-0402-1 · Cited by 597
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Lai, H., Li, Y., He, Y., Chen, F., Mi, B., Li, J., Xie, J., Ma, G., Yang, J., Xu, K., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2197837 · Cited by 208
Role of gut microbiota in functional constipation
Zhang, S., Wang, R., Li, D., Zhao, L., & Zhu, L. (2021) · Gastroenterology Report · doi:10.1093/gastro/goab035 · Cited by 175
Pan, R., Wang, L., Xu, X., Chen, Y., Wang, H., Wang, G., Zhao, J., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14183704 · Cited by 149
Metadata
- Authors
- Ibarra, A., Latreille-Barbier, M., Donazzolo, Y., Pelletier, X., & Ouwehand, A. C.
- Affiliations
- DuPont (Finland) (FI)
- Eurofins Optimed SAS, Clinical Research, Gières, France
- Eurofins (France) (FR)
- Corresponding author
- Ibarra, Alvin
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2018-02-08
- Volume
- 9
- Issue
- 3
- Pages
- 236-251
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- PMC
- PMC6219592
- OpenAlex
- W2773593508
- Cited by
- 121
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 26 · 2023: 17 · 2022: 17 · 2021: 10 · 2020: 11 · 2019: 9 · 2018: 1
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Gut Microbes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- DuPont
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- functional constipation, colonic transit time, probiotic supplementation, stool frequency, straining, stool consistency, quality of life, dose-ranging, adverse events
- MeSH terms
- Bifidobacterium animalis, Adolescent, Adult, Aged, Constipation, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Male, Middle Aged, Placebos, Quality of Life, Treatment Outcome, Probiotics, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. https://app.cochat.ai/papers/10.1080/19490976.2017.1412908
- The paper
- Ibarra, A., Latreille-Barbier, M., Donazzolo, Y., Pelletier, X., & Ouwehand, A. C. (2018). Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. https://doi.org/10.1080/19490976.2017.1412908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.